Bioxcel Therapeutics logo

BTAI

Bioxcel Therapeutics

$18.15

Earnings Summary

Revenue
$0Mn
Net Profits
$-31.47Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Bioxcel Therapeutics’s revenue fell -100% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Bioxcel Therapeutics has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Bioxcel Therapeutics’s net profit fell -19.32% since last year same period to $-31.47Mn in the Q1 2022. On a quarterly growth basis, Bioxcel Therapeutics has generated -20.47% fall in its net profits since last 3-months.

Net Profit Margins:

Bioxcel Therapeutics’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Bioxcel Therapeutics has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Bioxcel Therapeutics post its latest quarter earnings

EPS Estimate Current Quarter
-1.29
EPS Estimate Current Year
-1.29

Highlights

EPS Estimate Current Quarter:

Bioxcel Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -1.29 - a 2.27% jump from last quarter’s estimates.

EPS Estimate Current Year:

Bioxcel Therapeutics’s earning per share (EPS) estimates for the current year stand at -1.29.

Key Ratios

Key ratios of the Bioxcel Therapeutics post its Q2 2022 earnings

Earning Per Share (EPS)
-1.35
Return on Assets (ROA)
-0.33
Return on Equity (ROE)
-0.74

Highlights

Earning Per Share (EPS):

Bioxcel Therapeutics’s earning per share (EPS) fell -21.62% since last year same period to -1.35 in the Q2 2022. This indicates that the Bioxcel Therapeutics has generated -21.62% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bioxcel Therapeutics’s return on assets (ROA) stands at -0.33.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bioxcel Therapeutics’s return on equity (ROE) stands at -0.74.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-1.1
-1.12
-1.82%
2022-08-11
-1.2
-1.35
-12.5%

Company Information

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Organisation
Bioxcel Therapeutics
Headquarters
555 Long Wharf Drive, New Haven, CT, United States, 06511
Employees
89
Industry
Health Technology
CEO
Vimal Mehta

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*